Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13178194 | 0.87 | PIK3CA (0.49) | PIK3CAHDAC6PIK3CBPIK3CDPIK3CG | |
| SCHEMBL13178303 | 0.84 | PIK3CA (0.49) | PIK3CAHDAC6PIK3CBPIK3CDPIK3CG | |
| SCHEMBL12994698 | 0.83 | PIK3CA (0.54) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12994792 | 0.83 | PIK3CA (0.52) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL1687253 | 0.82 | PIK3CA (0.49) | PIK3CAHDAC6PIK3CBPIK3CDPIK3CG | |
| SCHEMBL12313618 | 0.81 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12994731 | 0.81 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12994793 | 0.80 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12994625 | 0.79 | PIK3CA (0.59) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12995035 | 0.79 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885HDAC6 124/4885PIK3CB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.